The entire U.S. healthcare system is planning, preparing, and collaborating to manage the COVID-19 pandemic. In order to maintain continuous supply chains, manufacturers in the adrenocorticotropic hormone (ACTH) market are striving to understand care patterns of high-risk patients and those with respiratory diseases. Manufacturers are establishing robust supply chains with urgent care centers, retail clinics in pharmacies, and workplace clinics to keep economies running during the pandemic. Since emergency departments are already stretched thin, these sites can act like wetlands to help absorb part of the overflow of patients with or without illnesses.
Telehealth services is emerging as a new business model for stakeholders in the adrenocorticotropic hormone (ACTH) market. These services are found to be most effective first line of access for non-elderly Americans with mild illness or with a risk of COVID-19.
-market-infographic.jpg)
The adrenocorticotropic hormone (ACTH) market is expected to surpass US$ 1.91 Bn by 2031. However, possible side effects of ACTH such as bone loss, indigestion, and muscle weakness are causing concerns among patients, pertaining to corticotropin as parenteral solution for injection. Hence, manufacturers are working closely with healthcare providers to create awareness about the management of side effects.
ACTH is being made available online for screening of patients presumed to have adrenocortical insufficiency. The growing incidence of stress and anxiety among individuals is acting as a key driver of the market, since stress may increase ACTH secretion in the body. On the other hand, ACTH is being used therapeutically as a drug to treat multiple sclerosis and infantile spasms.
ACTH blood tests are used in conjunction with cortisol tests to help detect, diagnose, and monitor conditions associated with excessive or deficient cortisol. The high prevalence of Cushing’s disease, Cushing syndrome, Addison disease, and hypopituitarism are contributing to the growth of the adrenocorticotropic hormone (ACTH) market, which is slated to clock a CAGR of 3.9% during the forecast period.
Measuring both cortisol and ACTH can help to differentiate different health conditions since the level of ACTH normally changes in the opposite direction to the level of cortisol. Since too much cortisol can lead to health issues such as acne, obesity, red face, and the likes, such findings are generating revenue opportunities for stakeholders in the adrenocorticotropic hormone (ACTH) market.
Individuals with insufficient cortisol production may exhibit symptoms including fatigue, diarrhea, and increased skin pigmentation. Such health issues are increasing revenue flow in the adrenocorticotropic hormone (ACTH) market. While ACTH is used to diagnose adrenal insufficiency, the ACTH stimulation test is being preferred for diagnosis. However, taking certain medications including oral, steroid or topical may cause abnormal results. Awareness is being created about the shortcomings of ACTH stimulation tests and management techniques are being implemented to avoid abnormal test results.
In addition to excess of ACTH from the pituitary gland, it can also generate from elsewhere in the body. This medical condition is known as ectopic production of ACTH, which is generated from tumors in different parts of the body.
-market-segmentation.jpg)
Analysts’ Viewpoint
Trust-based relationships are gaining prominence during the COVID-19 pandemic, which involve reliable community organizations educating patients about precautions to be taken during the ongoing pandemic situation. Conditions such as ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH) tend to exhibit glucocorticoid resistance. Such findings are creating value-grab opportunities for companies in the adrenocorticotropic hormone (ACTH) market. It has been found that corticotropin as a parenteral solution for injection can lead to possible side effects including back pain, menstrual irregularities, and hyperpigmentation. Hence, stakeholders in the adrenocorticotropic hormone (ACTH) market should work closely with clinicians and healthcare providers to increase awareness about effective management of side effects to improve patient outcomes.
|
Attribute |
Detail |
|
Market Size Value in 2020 (Base Year) |
US$ 1.3 Bn |
|
Market Forecast Value in 2031 |
US$ 1.91 Bn |
|
Growth Rate (CAGR) |
3.9% |
|
Forecast Period |
2021-2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, parent industry overview, etc. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon Request |
|
Pricing |
Available upon Request |
Adrenocorticotropic hormone (ACTH) market is expected to surpass US$ 1.91 Bn by 2031
Adrenocorticotropic hormone (ACTH) market is projected to expand at a CAGR of 3.9% from 2021 to 2031
Adrenocorticotropic hormone (ACTH) market is driven by rise in prevalence of various chronic diseases and rise in investments in research & development by key players
North America dominated the global adrenocorticotropic hormone (ACTH) market in 2020 and the trend is likely to continue during the forecast period
Key players operating in the global adrenocorticotropic hormone (ACTH) market include Mallinckrodt plc, Pfizer, Inc., Novartis AG, Merck KGaA, Ferring B.V., Avantor, Inc., Viatris, Inc., Hikma Pharmaceuticals plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Adrenocorticotropic Hormone (ACTH) Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Top 3 Players Operating in the Market Space
5.2. Regulatory Scenario
5.3. Export-Import Scenario
5.4. Comparison Study of Synthetic & Natural Adrenocorticotropic Hormone
5.5. Pipeline Analysis
5.6. COVID-19 Pandemic Impact on Industry
6. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Source
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Source, 2017–2031
6.3.1. Natural
6.3.2. Synthetic
6.4. Market Attractiveness Analysis, by Source
7. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Rheumatology
7.3.2. Neurology
7.3.3. Nephrotic Syndrome
7.3.4. Ophthalmology
7.3.5. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Source, 2017–2031
10.2.1. Natural
10.2.2. Synthetic
10.3. Market Value Forecast, by Indication, 2017–2031
10.3.1. Rheumatology
10.3.2. Neurology
10.3.3. Nephrotic Syndrome
10.3.4. Ophthalmology
10.3.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Source
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Source, 2017–2031
11.2.1. Natural
11.2.2. Synthetic
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Rheumatology
11.3.2. Neurology
11.3.3. Nephrotic Syndrome
11.3.4. Ophthalmology
11.3.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Source
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-Region
12. Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Source, 2017–2031
12.2.1. Natural
12.2.2. Synthetic
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Rheumatology
12.3.2. Neurology
12.3.3. Nephrotic Syndrome
12.3.4. Ophthalmology
12.3.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Source
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-Region
13. Latin America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Source, 2017–2031
13.2.1. Natural
13.2.2. Synthetic
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Rheumatology
13.3.2. Neurology
13.3.3. Nephrotic Syndrome
13.3.4. Ophthalmology
13.3.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Source
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-Region
14. Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Source, 2017–2031
14.2.1. Natural
14.2.2. Synthetic
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Rheumatology
14.3.2. Neurology
14.3.3. Nephrotic Syndrome
14.3.4. Ophthalmology
14.3.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-Region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Source
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-Region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Ambio Pharm, Inc.
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Armor Pharma
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Avantor, Inc.
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. BCN Peptides S.A.
15.3.4.1. Company Description
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. BIOVECTRA
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Ferring B.V.
15.3.6.1. Company Description
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Hikma Pharmaceuticals plc
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Mallinckrodt Pharmaceuticals
15.3.8.1. Company Description
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Merck KGaA
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Financial Overview
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Novartis AG
15.3.10.1. Company Description
15.3.10.2. Business Overview
15.3.10.3. Financial Overview
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
15.3.11. Novus Biologicals
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. Financial Overview
15.3.11.4. Strategic Overview
15.3.11.5. SWOT Analysis
15.3.12. Pfizer, Inc.
15.3.12.1. Company Description
15.3.12.2. Business Overview
15.3.12.3. Financial Overview
15.3.12.4. Strategic Overview
15.3.12.5. SWOT Analysis
15.3.13. Piramal Pharma Solutions
15.3.13.1. Company Description
15.3.13.2. Business Overview
15.3.13.3. Financial Overview
15.3.13.4. Strategic Overview
15.3.13.5. SWOT Analysis
15.3.14. PolyPeptide Group
15.3.14.1. Company Description
15.3.14.2. Business Overview
15.3.14.3. Financial Overview
15.3.14.4. Strategic Overview
15.3.14.5. SWOT Analysis
15.3.15. SAJJALA BIO LABS
15.3.15.1. Company Description
15.3.15.2. Business Overview
15.3.15.3. Financial Overview
15.3.15.4. Strategic Overview
15.3.15.5. SWOT Analysis
15.3.16. Sichuan Xieli Pharmaceutical Co., Ltd.
15.3.16.1. Company Description
15.3.16.2. Business Overview
15.3.16.3. Financial Overview
15.3.16.4. Strategic Overview
15.3.16.5. SWOT Analysis
15.3.17. Viatris Inc.
15.3.17.1. Company Description
15.3.17.2. Business Overview
15.3.17.3. Financial Overview
15.3.17.4. Strategic Overview
15.3.17.5. SWOT Analysis
List of Tables
Table 01: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 02: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 03: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 07: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 11: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 15: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 19: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031
Table 23: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figure
Figure 01: Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Source, 2020
Figure 03: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Indication, 2020
Figure 04: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Distribution Channel, 2020
Figure 05: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 06: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 07: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Natural, 2017–2031
Figure 08: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Synthetic, 2017–2031
Figure 09: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031
Figure 10: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 11: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Rheumatology, 2017‒2031
Figure 12: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Neurology, 2017‒2031
Figure 13: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Nephrotic Syndrome, 2017‒2031
Figure 14: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Ophthalmology, 2017‒2031
Figure 15: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Others, 2017–2031
Figure 16: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 17: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 18: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 19: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 20: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 21: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Region, 2020 and 2031
Figure 22: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Region, 2021–2031
Figure 23: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 24: North America Adrenocorticotropic Hormone (ACTH) Market Value Share, by Country, 2020 & 2031
Figure 25: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country, 2021–2031
Figure 26: North America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 27: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 28: North America Adrenocorticotropic Hormone (ACTH) Market Value Share (%), by Indication, 2020 and 2031
Figure 29: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 30: North America Adrenocorticotropic Hormone (ACTH) Market Value Share (%), by Distribution Channel, 2020 and 2031
Figure 31: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 32: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031
Figure 33: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 34: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 35: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 36: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 37: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031
Figure 38: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 39: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 40: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 41: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031
Figure 42: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 43: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 44: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 45: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 46: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031
Figure 47: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 48: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 49: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 50: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031
Figure 51: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 52: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 53: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 54: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 55: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031
Figure 56: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 57: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 58: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 59: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031
Figure 60: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 61: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 62: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031
Figure 63: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031
Figure 64: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031
Figure 65: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031
Figure 66: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 67: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Adrenocorticotropic Hormone [ACTH] Market Trends, 2021-2031
